DAN-G
Marke : CLS Cell Lines Service
DAN-G Cells
General information
Description | The DAN-G cell line is derived from a human pancreatic carcinoma. It is extensively utilized in research focused on pancreatic cancer, particularly in studies pertaining to tumorigenesis, metastasis, and chemotherapy resistance. The genetic profile of DAN-G includes mutations in key oncogenes and tumor suppressor genes, which are characteristic of pancreatic adenocarcinomas. This makes the cell line a valuable model for understanding the molecular mechanisms underlying pancreatic cancer and for testing new therapeutic strategies. In addition to its applications in cancer research, the DAN-G cell line has been used to study the cellular processes involved in the progression of pancreatic ductal adenocarcinoma, including cell cycle regulation, apoptosis, and signal transduction pathways. The cells exhibit aggressive in vitro growth characteristics and have the ability to form tumors in immunocompromised mice, which simulates the human disease and provides an in vivo system for evaluating the efficacy of anticancer drugs. Researchers also employ this cell line to investigate the role of the tumor microenvironment in pancreatic cancer progression and resistance to therapy. |
---|---|
Organism | Human |
Tissue | Pancreas |
Disease | Adenocarcinoma |
Synonyms | Dan-G, DanG, DANG |
Characteristics
Age | 68 years |
---|---|
Gender | Female |
Morphology | Epithelial-like |
Growth properties | Adherent |
Identifiers / Biosafety / Citation
Citation | DAN-G (Cytion catalog number 300162) |
---|---|
Biosafety level | 1 |
Expression / Mutation
Protein expression | p53 negative |
---|---|
Tumorigenic | Yes, in nude mice |
Mutational profile | DAN-G cells carry a homozygous Kras mutation in codon12: GGT(Gly) >GTT(Val) |
Handling
Culture Medium | RPMI 1640, w: 2.1 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
---|---|
Medium supplements | Supplement the medium with 10% FBS |
Passaging solution | Accutase |
Doubling time | 33 hours |
Subculturing | Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. |
Split ratio | A ratio of 1:4 to 1:8 is recommended |
Seeding density | 3 to 4 x 10^4 cells/cm^2 will yield in a confluent layer in about 4 days |
Fluid renewal | 2 to 3 times per week |
Freezing recovery | After thawing, plate the cells at 5 x 10^4 cells/cm^2 and allow the cells to recover from the freezing process and to adhere for at least 24 hours. |
Freeze medium | CM-1 (Cytion catalog number 800100) or CM-ACF (Cytion catalog number 806100) |
Handling of cryopreserved cultures |
|
Quality control / Genetic profile / HLA
Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
---|---|
STR profile | Amelogenin: x,x CSF1PO: 13 D13S317: 8 D16S539: 8,11 D5S818: 12,13 D7S820: 10,13 TH01: 9.3 TPOX: 10 vWA: 16,18 D3S1358: 16 D21S11: 29,31.2 D18S51: 16 Penta E: 7 Penta D: 9,13 D8S1179: 10,11 FGA: 20 D1S1656: 12,17 D6S1043: 12 D2S1338: 17,18 D12S391: 17,20 D19S433: 13,14 |
HLA alleles | A*: 02:01:01 B*: 07:02:01, 13:02:01 C*: 06:02:01, 07:02:01 DRB1*: 07:01:01, 15:01:01 DQA1*: 01:02:01, 02:01:01 DQB1*: 02:02:01, 06:02:01 DPB1*: 04:01:01, 17:01:01 E: 01:03:02 |